GlassScriptPhysician profile
John Edgar Kleckley
NPI 1356544100
$19,299.93
in general payments reported to CMS, 2019-2025
27 companies · $385 in 2025
The $385 reported for 2025 was more than what a typical Geriatric Medicine (Internal Medicine) provider received nationally (typical 2025 total: $123).
See the full distribution for Geriatric Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2022: $42.32 · 2023: $415 · 2024: $318 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,117.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $17,918.11 | 2019 | |
| Abbvie INC. | $172.93 | 2022-2025 | |
| Boston Scientific Corporation | $135.45 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $132.84 | 2023-2025 | Rexulti |
| Pfizer INC. | $88.26 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $86.39 | 2019 | |
| Glaxosmithkline, LLC. | $77.73 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lundbeck LLC | $72.53 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $67.95 | 2023-2024 | Auvelity |
| Eisai INC. | $53.85 | 2025 | |
| Abbott Laboratories | $52.48 | 2023-2024 | Infinity, Freestyle Libre |
| Sumitomo Pharma America, INC. | $50.01 | 2023 | Gemtesa |
| Lilly USA, LLC | $48.84 | 2023-2025 | Kisunla, Jardiance, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $48.13 | 2024-2025 | Farxiga, Airsupra |
| Teva Pharmaceuticals USA, INC. | $40.20 | 2025 | Austedo Xr |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $34.50 | 2024 | Ozempic, Rybelsus |
| Amneal Pharmaceuticals LLC | $34.18 | 2024 | Unithroid |
| Recor Medical INC | $25.69 | 2025 | Paradise Ultrasound Renal Denervation System |
| Phadia US INC. | $24.87 | 2024 | Immunocap |
| Axonics, INC. | $20.53 | 2023 | Axonics |
| Medtronic, INC. | $20.45 | 2023 | Interstim |
| Astellas Pharma US INC | $16.93 | 2023 | Veozah |
| Merck Sharp & Dohme LLC | $16.73 | 2025 | Capvaxive |
| Novartis Pharmaceuticals Corporation | $15.50 | 2022 | |
| Edwards Lifesciences Corporation | $15.26 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| C2n Diagnostics, LLC | $14.88 | 2025 | Precivityad2 |
| Noven Therapeutics, LLC | $14.71 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kleckley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.